Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMO pembrolizumab in relapsed or metastatic osteosarcoma
2016-001676-29Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Sep 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in osteosarcoma (OS), sponsored by Oslo University Hospital. Primary endpoint: Clinical response rate at 18 weeks. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2016-001676-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001676-29.